We used microarrays to identify markers predicting responder status in infliximab treatment in 19 rheumatoid arthritis and 20 Crohn's disease patients at week 0 and week 2 of treatment.
Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease.
Specimen part, Disease, Disease stage, Treatment, Subject, Time
View Samples